CSL Names Paul McKenzie as Chief Operating Officer

Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.

KING OF PRUSSIA, PA – 15th May 2019 - CSL today named Dr. Paul McKenzie, an accomplished global leader with diverse biotechnology experience, as Chief Operating Officer (COO), effective 3rd June 2019. 

“Paul has a demonstrated track record of success in leading operational excellence and he brings significant leadership capabilities that will continue to drive CSL’s sustainable growth,” said CSL CEO & Managing Director Paul Perreault. “Throughout his 30-year career, Paul has earned a reputation as a patient-focused business leader -- an important attribute as we continue to invest in our science, facilities and commercial capabilities for delivering better outcomes to patients and protecting public health. I look forward to working with Paul and the rest of our leadership team in executing our strategy and continuing to sustainably grow our global business.”

Dr. McKenzie, 53, has served in a range of progressive operational leadership roles in the biopharma and biotech industries since 1992. Most recently, he was Executive Vice President of Pharmaceutical Operations & Technology at Biogen where he was accountable for asset management, technical development, global manufacturing, supply chain operations, CMC regulatory, quality and engineering. Dr. McKenzie also held leadership roles in research & development, science & technology and operations with Johnson & Johnson, Bristol-Myers Squibb and Merck earlier in his career.

He earned his Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and was awarded his Ph.D. in Chemical Engineering from Carnegie Mellon University. Dr. McKenzie is an accomplished author and thought leader on operational excellence in the biotech industry.

Dr. McKenzie, who will be based at CSL Behring’s operational headquarters in King of Prussia (PA), will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy. This includes manufacturing, manufacturing technical support, CSL Plasma, quality, engineering, environment, health & safety (EHS), business technology, planning, logistics, sourcing, business services and enterprise excellence. 

“Now is an incredibly exciting time to be a part of CSL. I am thrilled to join a growing global biotech leader and a well-established management team that is keenly focused on creating value for shareholders, patients, employees and the communities in which it operates,” Dr. McKenzie said. “I look forward to contributing to CSL’s future growth and success in delivering on the promise of innovative medicines to treat patients and protect public health around the world.”

About CSL
CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 60 countries and employs 22,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visit 
www.csl.com

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries. For inspiring stories about the promise of biotechnology, visit Vita  CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.

# # #

CSL Media Contact
Christina Hickie
CSL Limited
Phone: +61 9389 3425/ 0429 609 762
Christina.Hickie@csl.com.au